Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $4,049,989 | $4,129,409 | $3,976,060 |
| % Growth | – | -1.9% | 3.9% | – |
| Cost of Goods Sold | – | $2,718,168 | $2,626,853 | $2,513,409 |
| Gross Profit | – | $1,331,821 | $1,502,556 | $1,462,651 |
| % Margin | – | 32.9% | 36.4% | 36.8% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $751,003 | $747,855 | $665,098 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $353,471 | $137,440 | $146,578 |
| Operating Expenses | – | $1,104,474 | $885,295 | $811,676 |
| Operating Income | – | $227,347 | $617,261 | $650,975 |
| % Margin | – | 5.6% | 14.9% | 16.4% |
| Other Income/Exp. Net | – | -$134,233 | -$35,977 | -$27,988 |
| Pre-Tax Income | – | $93,114 | $581,284 | $622,987 |
| Tax Expense | – | $67,823 | $100,914 | $130,379 |
| Net Income | – | $10,297 | $474,624 | $486,226 |
| % Margin | – | 0.3% | 11.5% | 12.2% |
| EPS | – | 0.2 | 9.27 | 9.57 |
| % Growth | – | -97.8% | -3.1% | – |
| EPS Diluted | – | 0.2 | 9.22 | 9.48 |
| Weighted Avg Shares Out | – | 51,380 | 51,227 | 50,812 |
| Weighted Avg Shares Out Dil | – | 51,628 | 51,451 | 51,301 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $8,575 | $5,196 | $780 |
| Interest Expense | – | $126,288 | $136,710 | $59,291 |
| Depreciation & Amortization | – | $361,741 | $314,124 | $303,870 |
| EBITDA | – | $581,143 | $1,032,118 | $986,148 |
| % Margin | – | 14.3% | 25% | 24.8% |